Rabbit Polyclonal ARV1(N-term) Antibody

+ +

•  

   
     All lanes : Anti-ARV1 Antibody  (N-term) at 1:2000 dilution Lane 1: 293T/17 whole cell lysate Lane 2: human kidney lysate Lane 3: HL-60 whole cell lysate Lane 4: K562 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 31 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     ARV1 Antibody  (N-term) (Cat. #P33593) western blot analysis in A2058 cell line lysates (35ug/lane).This demonstrates the ARV1 antibody detected the ARV1 protein (arrow).    

•  

   
     ARV1 Antibody  (N-term) (Cat. #P33593) western blot analysis in mouse Neuro-2a cell line lysates (35ug/lane).This demonstrates the ARV1 antibody detected the ARV1 protein (arrow).    

•  

   
     Overlay histogram showing A2058 cells stained with P33593(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P33593,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     ARV1 antibody (N-term) (Cat. #P33593) immunohistochemistry analysis in formalin fixed and paraffin embedded human skeletal muscle followed by peroxidase conjugation of the secondary antibody and DAB staining.  This data demonstrates the use of the ARV1 antibody (N-term) for immunohistochemistry.  Clinical relevance has not been evaluated.    

The ARV1 (N-term) antibody is designed to target the N-terminal region of the ARV1 (Accelerated Recovery Virtual 1) protein, a conserved eukaryotic protein implicated in lipid homeostasis and intracellular trafficking. ARV1. first identified in yeast, localizes to the endoplasmic reticulum (ER) and Golgi apparatus, where it facilitates vesicle-mediated transport of glycosylphosphatidylinositol (GPI)-anchored proteins and sterols. Studies suggest ARV1 plays a role in maintaining ER morphology, lipid droplet formation, and cellular stress responses. Dysregulation of ARV1 has been linked to neurological disorders, including seizures and developmental delays, as well as metabolic conditions such as hypercholesterolemia.

The ARV1 (N-term) antibody is commonly generated in rabbits or mice using synthetic peptides or recombinant protein fragments corresponding to the protein's N-terminal domain (typically residues 1-100). This region is critical for ARV1’s function in lipid binding and protein interactions. Validated for applications like Western blotting, immunofluorescence, and immunohistochemistry, the antibody helps detect endogenous ARV1 expression across tissues, with high specificity confirmed via knockout controls. Its use has advanced research into ARV1’s role in neurodegenerative diseases, lipid metabolism, and ER-associated degradation pathways. Commercial variants often include monoclonal and polyclonal options, optimized for diverse experimental models.